Zheng Long-Yi, Xu Xia, Wan Ren-Hui, Xia Sheng, Lu Jin, Huang Qin
1Department of Endocrinology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433 China.
2Department of Rheumatology and Immunology, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai, 200433 China.
Diabetol Metab Syndr. 2019 Jul 24;11:60. doi: 10.1186/s13098-019-0455-5. eCollection 2019.
Visfatin is a multifaceted protein that plays an important role in regulating a variety of physiological and pathological processes, including obesity, diabetes and cardiovascular disease. However, circulating visfatin levels in atherosclerosis plaque progression in patients with type 2 diabetes, or its association with the vascular territory affected remain unclear.
We evaluated the relationship between visfatin levels and carotid or femoral artery atherosclerosis in Chinese patients with type 2 diabetes. Serum levels of visfatin were measured by enzyme-linked immunosorbent assay (ELISA) in 97 inpatients with type 2 diabetes. Carotid and/or femoral atherosclerotic plaques were detected by B-mode ultrasound.
Serum visfatin levels were elevated in the group with atherosclerotic plaques compared to the control group without plaques [0.68 (0.46-1.58) versus 0.45 (0.23-0.76) ng/mL, respectively, = 0.0002]. Patients with carotid plaques showed higher visfatin levels than those with or without femoral plaques. Pearson's correlation analysis showed that serum visfatin levels were positively correlated with waist circumference ( = 0.226, = 0.029), waist-hip ratio ( = 0.221, = 0.032), TG ( = 0.222, = 0.030) and number of plaques ( = 0.275, = 0.009). Logistic regression analysis showed that a higher serum visfatin level was an independent predictor for the presence of atherosclerotic plaques.
In conclusion, among patients with T2DM, serum visfatin levels were elevated in those with atherosclerotic plaques, especially in patients with carotid atherosclerotic plaques. Serum visfatin may serve as a predictor of atherosclerotic plaques in patients with T2DM.
内脂素是一种多功能蛋白质，在调节多种生理和病理过程中发挥重要作用，包括肥胖、糖尿病和心血管疾病。然而，2型糖尿病患者动脉粥样硬化斑块进展过程中循环内脂素水平，或其与受影响血管区域的关联仍不清楚。
我们评估了中国2型糖尿病患者内脂素水平与颈动脉或股动脉粥样硬化之间的关系。采用酶联免疫吸附测定（ELISA）法检测97例2型糖尿病住院患者的血清内脂素水平。通过B型超声检测颈动脉和/或股动脉粥样硬化斑块。
与无斑块的对照组相比，有动脉粥样硬化斑块的组血清内脂素水平升高[分别为0.68（0.46 - 1.58）与0.45（0.23 - 0.76）ng/mL，P = 0.0002]。有颈动脉斑块的患者内脂素水平高于有或无股动脉斑块的患者。Pearson相关性分析显示，血清内脂素水平与腰围（r = 0.226，P = 0.029）、腰臀比（r = 0.221，P = 0.032）、甘油三酯（r = 0.222，P = 0.030）和斑块数量（r = 0.275，P = 0.009）呈正相关。Logistic回归分析显示，较高的血清内脂素水平是动脉粥样硬化斑块存在的独立预测因素。
总之，在2型糖尿病患者中，有动脉粥样硬化斑块的患者血清内脂素水平升高，尤其是有颈动脉粥样硬化斑块的患者。血清内脂素可能作为2型糖尿病患者动脉粥样硬化斑块的预测指标。
